Clinical Trials

This protocol outlines a prospective data collection effort from Allergy specialists at several academic and clinical institutions with the main goal of establishing and achieving a broad network and collection of allergy data consisting of clinical data and patient reported outcomes. 

The purpose of this study is to evaluate a serum IgE hemp antibody immunoassay for use in the evaluation of allergies to cannabis and other hemp products.

Cannabis, in its various forms, has been used for decades recreationally, and medicinally throughout the world.  Recent changes in the legal status of recreational cannabis as well as medical marijuana has meant that more and more individuals are being exposed to its potential allergens.

Currently, there is no reliable blood testing method to test patients for a potential allergy to cannabis.  Without a reliable testing method, many patients who currently ...

The purpose of this study is to build a Mayo Clinic registry of data and biobank from subjects with drug allergy. The data collected will include demographic, diagnostic, and health data on a large group of patients to discover novel drug allergy diagnostic methods.

The goal is to assess the criterion and predictive validity of the diagnostic criteria for anaphylaxis proposed by the 2nd Symposium on the Definition and Management of Anaphylaxis. Determination of the clinical utility of the diagnostic criteria is essential for the criteria to be widely adopted into clinical practice.  Prospectively, the NIAID/FAAN criteria continued to be highly sensitive (95%) but had lower specificity (71%) than on retrospective assessment. These criteria are likely to be useful for the diagnosis of anaphylaxis in the ED.